SGN-STNV

N/A

Report date: 2024/02/05 14:07:52

Base Information

Drug NameSGN-STNV

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitors

TargetsTubulin

Therapy Area/IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[12]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesItaly +[6]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesSeagen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSeagen Inc

Active IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[11]

Inactive IndicationsAdenocarcinoma

Other Information

ATC CodeN/A